Literature DB >> 19210109

Esomeprazole: a proton pump inhibitor.

Ravi Vachhani1, Gregory Olds, Vic Velanovich.   

Abstract

Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001. Esomeprazole is indicated for the treatment of gastroesophageal reflux disease in adults and children, risk reduction of NSAIDs-associated gastric ulcer, Helicobacter pylori eradication and control of pathological hypersecretory conditions associated with Zollinger-Ellison syndrome. Esomeprazole is available in both oral and intravenous formulations. A number of studies have compared esomeprazole with other PPIs. While differences supporting esomeprazole have been reported, the magnitude of differences has been variable and of uncertain clinical importance. Cost plays a major role in prescribing patterns of PPIs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210109     DOI: 10.1586/17474124.3.1.15

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  3 in total

1.  Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus.

Authors:  Kathleen O'Connell; Vic Velanovich
Journal:  Surg Endosc       Date:  2010-07-30       Impact factor: 4.584

2.  Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction.

Authors:  Ravi Vachhani; Doumit Bouhaidar; Alvin Zfass; Bimaljit Sandhu; Ali Nawras
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

Review 3.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.